HARMONi-2
The first head-to-head trial in which a new drug beat Keytruda, in China; a survival benefit followed in 2026.
398 patients. PFS 11.1 vs 5.8 months (HR 0.51, WCLC 2024). In 2026 Akeso and Summit reported a statistically significant overall survival benefit for ivonescimab monotherapy versus pembrolizumab. Single-country trial; Western confirmation rests on HARMONi-3 and HARMONi-7.
- Median 11.1 vs 5.8 months with Ivonescimab compared with Pembrolizumab; about 5.3 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 49 percent lower chance of the event at any given time (hazard ratio 0.51, likely range 0.38 to 0.69).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: First-line PD-L1-positive (TPS ≥1%) advanced NSCLC in China: ivonescimab vs pembrolizumab monotherapy. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (PD-L1); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
398 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (IRRC)primary | Ivonescimab | 198 | 11.1 months | 0.51 (0.38–0.69) | <0.0001 | link |
| Pembrolizumab | 200 | 5.8 months |
Pages like this
not linked directly; found by shared links- TrialHARMONi-3
Shares Ivonescimab, Pembrolizumab, Non-small-cell lung cancer.
- PersonWenfeng Fang
Shares Ivonescimab, VEGF / VEGFR, PD-1, Non-small-cell lung cancer.
- Key paperHARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer
Shares Caicun Zhou, Ivonescimab, VEGF / VEGFR, PD-1.
- InstitutionShanghai Pulmonary Hospital
Shares Caicun Zhou, PD-1, Non-small-cell lung cancer.
- TrialKEYNOTE-775 / Study 309
Shares VEGF / VEGFR, PD-1, Pembrolizumab.
- CompanySummit Therapeutics
Shares Ivonescimab, Non-small-cell lung cancer.
- PairingLenvatinib + pembrolizumab (pMMR endometrial cancer after platinum)
Shares VEGF / VEGFR, PD-1, Pembrolizumab.
- TrialKEYNOTE-024 & KEYNOTE-189
Shares PD-1, Pembrolizumab, Non-small-cell lung cancer.